Search
for
Sort by
Research 61–90 of 69
- Scalp Pustule as a Manifestation of Erlotinib-Induced Skin Toxicity: Report of Two Cases and Literature Review
- A guide to diagnosis and management of hypertrichosis
- Erosive Pustular Dermatosis: Delving into Etiopathogenesis and Management
- Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody–drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and Venereology
- Cancer-Related Alopecia Risk and Treatment
- Spotlight commentary: Navigating the cutaneous side effects of chemotherapy
- Erlotinib-induced trichomegaly of eyelashes in lung cancer treatment: Epidermal growth factor receptor inhibitor side effect
- Effect of a medicinal and edible decoction YH0618 on chemotherapy-induced dermatologic toxicity: a randomized controlled trial
- Tumor Necrosis Factor-α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice
- Hypertrichosis of the pinnae in a patient using panitumumab
- Abnormal hair growth in patients (pts) with metastatic colorectal cancer (mCRC) treated with the anti-epidermal growth factor receptor (EGFr) monoclonal antibody (mAb) panitumumab (Pmab)
- PRIDE syndrome associated with panitumumab treatment – case report and literature review
- Perifollicular Xanthomas Associated with Epidermal Growth Factor Receptor Inhibitor Therapy
- Chemotherapy-induced iatrogenic injury of skin: New drugs and new concepts
- Dermatologic Reactions to Targeted Therapy
- PRIDE syndrome with lumbosacral hypertrichosis
- Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
- Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer
- Hair disorders in patients with cancer
- Alopecia in patients treated with molecularly targeted anticancer therapies
- Advances in the Management of Cutaneous Toxicities of Targeted Therapies
- Pathogenesis and treatment options for chemotherapy‐induced alopecia: a systematic review
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Alopecia in Association with Malignancy: A Review
- Role for the Epidermal Growth Factor Receptor in Chemotherapy-Induced Alopecia
- Epidermal growth factor, innovation and safety
- Madarosis, milphosis, eyelash trichomegaly, and dermatochalasis
- An overview of management of drug-induced hair and nail disorders
- Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
- Cutaneous Drug Eruptions Associated with the Use of Biologies and Cutaneous Drug Eruptions Mimicking Specific Skin Diseases